RotaTeq: Progress toward developing world access

Journal of Infectious Diseases

Volumn 202, Issue SUPPL. 1, 2010, Pages

  Goveia, Michelle G ^a,b   Nelson, Christopher B ^a   Ciarlet, Max ^b  

^a Medical Affairs and Policy ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

AFRICA; ASIA; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; GASTROENTERITIS; GENETIC REASSORTMENT; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; MALNUTRITION; NICARAGUA; PREMATURITY; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; WORLD HEALTH ORGANIZATION;

CLINICAL TRIALS AS TOPIC; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; INFANT NUTRITION DISORDERS; INFANT, NEWBORN; INFANT, PREMATURE; NICARAGUA; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 77955705608     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653546     Document Type: Review

References (37)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-572.
2. World Health Organization. WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 2007; 82(32):285-286.
3. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304-306.
4. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15:29-56.
5. Matthijnssens J, Rahman M, Ciarlet M, Van Ranst M. Emerging human rotavirus genotypes. In: Palombo E, Kirkwood CD, eds. Viruses in the environment. Kerala, India: Research Signpost, 2008:171-219.
6. Ciarlet M, Estes MK. Rotaviruses: basic biology, epidemiology and methodologies. In: Bitton G, ed. Encyclopedia of environmental microbiology. New York: John Wiley & Sons, 2002:2753-2773.
7. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
8. Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007; 119(1):11-18.
9. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009; 84:533-540.
10. Dennehy PH, Goveia MG, Dallas MJ, Heaton PM. The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine. Int J Infect Dis 2007; 11:S36-S42.
11. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess the risk of intussusception and other adverse events after pentavalent, bovine-derive rotavirus vaccine. Pediatr Infect Dis J 2010; 29:1-5.
12. Haber P, Patel M, Izurieta H, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008; 121:1206-1212.
13. Centers for Disease Control and Prevention. Delayed Onset and Diminished Magnitude of Rotavirus Activity: United States, November 2007-May 2008.MMWR Morb Mortal Wkly Rep 2008; 57(25):697-700.
14. Rodrigo C, Salman N, Tatochenki V, Meszner Z, Giaquinto C. Recommendadtions for rotavirus vaccination: a worldwide perspective. Vaccine 2010 (in press).
15. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007; 119(1):171-181.
16. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008; 46(S2):S38-S48.
17. Family Health International. Consensus statement of rotavirus disease and prevention (Asia-Pacific Rotavirus MetaForum). http:// www.fhi.org. Accessed 31 January 2008.
18. Georges-Courbot MC, Monges J, Siopathis MR, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142:405-411.
19. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2:108.
20. Hanlon P, Marsh V, Shenton F, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987; 1(8546): 1342-1345.
21. Lanata CF, Black RE, del Aguila R, et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989; 159:452-459.
22. Linhares AC, Lanata CF, Hausdorff WP, Gabbay YB, Black RE. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesushuman reassortant rotavirus vaccine efficacy trials: analysis by severity of diarrhea. Pediatr Infect Dis J 1999; 18:1001-1006.
23. Pérez-Schael I, Guntinas MJ, Pérez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-1187.
24. World Health Organization. WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 1999; 74(5):33-40.
25. World Health Organization. Rotavirus vaccines: an update. Wkly Epidemiol Rec 2003; 78(1):1-8.
26. World Health Organization. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol Rec 2006; 81(1):2-11.
27. World Health Organization. Immunization Standards. http://www who.int/immunization-standards/vaccine-quality/167-rotavirus/en/ index.html. Accessed 9 July 2010.
28. Rodriguez ZM, Goveia MG, Stek JE, et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007; 26:221-227.
29. Ciarlet M, Sani-Grasso R, Yuan G, et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008; 27:874-80.
30. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007; 26:1099-1104.
31. Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants RR-2 and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2009; 58:1-25.
32. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine. Pediatrics 2009; 123:1412-1420.
33. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Record of the proceedings. 27-28 June 2007. http://www.cdc.gov/vaccines/recs/acip/mtg-minutes-archive htm#2007. Accessed 9 July 2010.
34. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Vaccines for Children Program: vaccines to prevent rotavirus gastroenteritis. http://www.cdc.gov/vaccines/programs/ vfc/downloads/resolutions/0608rotavirus.pdf. Accessed 13 November 2008.
35. Amador JJ, Vasquez J, Orozco M, et al. Rotavirus disease burden, Nicaragua 2001-2005. Int J Infect Dis 2010; 14:e592-595.
36. Amador JJ. Early experiences with routine use of rotavirus vaccines: Nicaragua. Paper presented at: Eighth International Rotavirus Symposium; 3-4 June 2008; Istanbul, Turkey.
37. Mast TC, Espinoza F, Palacio del Carmen L, Khawaja S, Sanchez E, Nicaragua Rotavirus Surveillance Project Team. Effectiveness of the oral pentavalent rotavirus vaccine in Nicaragua. In: Program and abstracts of the 26th Annual meeting of the European Society for Pediatric Infectious Diseases; 4-8 May 2010; Nice, France. Abstract 596.